Roel Bogie

Chapter 3

Prevalence of LSTs Prevalence of patients with LSTs in neoplasm(s) Prevalence of LSTs of all neoplasms Location Endoscopic subtype Histology Males (%) Katano 2017 • • º R Therapy (ESD) NA 3 NA NA Burgess 2017 • • º P Therapy (EMR), LSTs ≥20mm NA 8 Mean 67.7* 53.2% * LST term used Serrated lesions excluded Study design Duration of study (years) Age of the study population (years)

Zhao 2014 • • • • • º P All indications FAP,IBD,SPS 101/2 Median 62 56.0% Xiang 2014 • º • R Therapy (EMR, ESD) FAP, IBD, SPS, Lynch syndrome, colonic resection 2 ? 65.4% Togashi 2014 • • •/ º P All indications, LSTs ≥20mm

Yamada 2016 • • • R Therapy (ESD, surgery) FAP, IBD 11 Mean 66 55.8%

Kudo 2015 • • • • • R Therapy (all) IBD 8 Mean 66.2 65.0%

NA 2 Mean 66.6 68.2%

Miyamoto 2014 • • • • R Therapy (all) FAP, IBD 5 Median 68 63.1% Konda 2014 • • • • P Therapy (all) FAP, IBD, Lynch syndrome

NA Mean 68.1 62.7%

Exclusion criteria

Inclusion criteria

LST

definition

Prevalence estimates LST features

Study

Table 3.1: Overview of all included studies.

44